Aquatic Capital Management LLC Purchases 17,146 Shares of Medpace Holdings, Inc. $MEDP

Aquatic Capital Management LLC grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 244.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 24,158 shares of the company’s stock after buying an additional 17,146 shares during the period. Aquatic Capital Management LLC owned 0.09% of Medpace worth $12,421,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC lifted its position in Medpace by 2.6% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the period. BOKF NA grew its position in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after buying an additional 20 shares during the period. HighPoint Advisor Group LLC raised its stake in shares of Medpace by 2.8% during the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after buying an additional 22 shares during the last quarter. Portside Wealth Group LLC lifted its holdings in Medpace by 2.5% in the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after buying an additional 27 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after buying an additional 27 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $450.41 on Monday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92. The company has a market capitalization of $12.78 billion, a PE ratio of 29.44, a PEG ratio of 2.16 and a beta of 1.44. The company has a 50 day moving average price of $523.62 and a two-hundred day moving average price of $539.41.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company had revenue of $708.45 million for the quarter, compared to analyst estimates of $689.53 million. During the same period last year, the business posted $3.67 earnings per share. The business’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Royal Bank Of Canada began coverage on shares of Medpace in a report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 target price for the company. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Finally, TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and dropped their price objective for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Five equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.